BridgeBio Pharma, Inc. (BBIO)

27,74 +0,71 (+2,63%) Alla chiusura: 04:00PM EDT

BridgeBio Pharma, Inc.

3160 Porter Drive
Suite 250
Palo Alto, CA 94304
United States
650 391 9740
https://bridgebio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 550

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Neil Kumar Ph.D.	Co-Founder, President, CEO & Director	1,53M	N/D	1979
Dr. Charles J. Homcy M.D.	Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director	563,2k	N/D	1948
Dr. Frank P. McCormick Ph.D.	Co-Founder, Chairman of Oncology & Director	542,78k	N/D	1950
Dr. Brian C. Stephenson C.F.A., Ph.D.	CFO & Secretary	1,15M	N/D	1981
Dr. Richard H. Scheller Ph.D.	Chairman of Research & Development	509,62k	N/D	1953
Dr. Uma Sinha Ph.D.	Chief Scientific Officer	1,31M	N/D	1958
Grace Rauh	Vice President of Communications	N/D	N/D	N/D
Mr. Eli M. Wallace Ph.D.	Chief Scientific Officer of Oncology	N/D	N/D	1967
Dr. Thomas Trimarchi Ph.D.	Chief Product Officer	N/D	N/D	N/D
Dr. Eric Michael David J.D., M.D., Ph.D.	Chief Executive Officer of Gene Therapy	N/D	N/D	1972

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Governance aziendale

L'ISS Governance QualityScore di BridgeBio Pharma, Inc. al 1 maggio 2024 è 10. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 10; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.